KALBITOR (ecallantide)
PLASMA KALLIKREIN INHIBITORS (ACUTE) · HEREDITARY ANGIOEDEMA
DYAX CORP./SHIR
Drug class
Plasma Kallikrein Inhibitors (Acute)
Plasma kallikrein inhibitors for acute use are a targeted therapeutic class of agents formulated to arrest the contact activation pathway during acute attacks of hereditary angioedema. Read more about Plasma Kallikrein Inhibitors (Acute)
2 drugs in this class 2 manufacturers
Drugs in Plasma Kallikrein Inhibitors (Acute)
EKTERLY (sebetralstat)
PLASMA KALLIKREIN INHIBITORS (ACUTE) · HEREDITARY ANGIOEDEMA
KALVISTA PHARMA
Filter & compare in the drug finder →
Opens the drug finder with Plasma Kallikrein Inhibitors (Acute) preselected. Add indication or manufacturer filters there.
Plasma kallikrein inhibitors for acute use are a targeted therapeutic class of agents formulated to arrest the contact activation pathway during acute attacks of hereditary angioedema.
These medications selectively bind to and inhibit active plasma kallikrein, preventing the enzymatic cleavage of high-molecular-weight kininogen and thereby halting the excessive generation of bradykinin, the principal mediator driving vascular permeability, vasodilation, and tissue edema.
Clinically, these fast-acting agents—such as ecallantide and oral formulations like sebetralstat—serve as on-demand rescue therapies to resolve acute episodes involving subcutaneous swelling, painful abdominal attacks, and potentially fatal laryngeal obstruction.
-
fda.gov
Plasma kallikrein inhibitors for acute use are a targeted therapeutic class of agents formulated to arrest the contact activation pathway during acute attacks of hereditary angioedema Clinically, these fast-acting agents—such as ecallantide and oral formulations like sebetralstat—serve as on-demand rescue therapies to resolve acute episodes involving subcutaneous swelling, painful abdominal attacks, and potentially fatal laryngeal obstruction
-
nih.gov
Plasma kallikrein inhibitors for acute use are a targeted therapeutic class of agents formulated to arrest the contact activation pathway during acute attacks of hereditary angioedema These medications selectively bind to and inhibit active plasma kallikrein, preventing the enzymatic cleavage of high-molecular-weight kininogen and thereby halting the excessive generation of bradykinin, the principal mediator driving vascular permeability, vasodilation, and tissue edema Clinically, these fast-act...
-
fda.gov
Clinically, these fast-acting agents—such as ecallantide and oral formulations like sebetralstat—serve as on-demand rescue therapies to resolve acute episodes involving subcutaneous swelling, painful abdominal attacks, and potentially fatal laryngeal obstruction
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.